Mohamad Bydon, Wenchun Qu, F M Moinuddin, Christine L Hunt, Kristin L Garlanger, Ronald K Reeves, Anthony J Windebank, Kristin D Zhao, Ryan Jarrah, Brandon C Trammell, Sally El Sammak, Giorgos D Michalopoulos, Konstantinos Katsos, Stephen P Graepel, Kimberly L Seidel-Miller, Lisa A Beck, Ruple S Laughlin, Allan B Dietz
Intrathecal delivery of autologous culture-expanded adipose tissue-derived mesenchymal stem cells (AD-MSC) could be utilized to treat traumatic spinal cord injury (SCI). This Phase I trial (ClinicalTrials.gov: NCT03308565) included 10 patients with American Spinal Injury Association Impairment Scale (AIS) grade A or B at the time of injury. The study's primary outcome was the safety profile, as captured by the nature and frequency of adverse events. Secondary outcomes included changes in sensory and motor scores, imaging, cerebrospinal fluid markers, and somatosensory evoked potentials...
April 1, 2024: Nature Communications